CassandraBio
Pipeline dossier

NIH & clinical-trial pipeline signals for MapLight Therapeutics, Inc. (MPLT)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for MPLT, mapped to public ticker MPLT (CIK 0001770069). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →
Trial → FilingMPLT35% conf

MapLight Therapeutics, Inc. (MPLT) — PHASE2 protocol updated 7 days ago

Upstream (observed)
Clinical trial status (PHASE2) — An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)
trial ↗filings ↗
Trial → FilingMPLT35% conf

MapLight Therapeutics, Inc. (MPLT) — PHASE2 protocol updated 7 days ago

Upstream (observed)
Clinical trial status (PHASE2) — A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)
trial ↗filings ↗

Recent SEC 8-K filings

JSON API for this entity →